. Our data provide multiple estimates for the mid-tolate Paleozoic increase in drilling frequencies. The evidence for late Mesozoic increase is more circumstantial, however, being based on the late Cenozoic (Holocene) estimates only. However, the Paleozoicto-Holocene increase is consistent with the Mesozoic Marine Revolution hypothesis. Moreover, recent literature compilations (4, 17) do not indicate any significant increase in drilling between Paleozoic and Mesozoic brachiopods (i.e., the post-Paleozoic increase must have happened either in the latest Mesozoic or in the Cenozoic). Also, recent case studies indicate that exceptionally high drilling frequencies are occasionally observed in Cenozoic brachiopods, yielding HDLT estimates as high as 40% (19) : a value higher than any of the 34 Paleozoic estimates reported here (Fig. 2) . 24. R. K. Bambach, Geobios 32, 131 (1999) . 25 . This argument is inconclusive when considered alone.
If the drillers were highly facultative and attacked brachiopods by drilling only occasionally, the low frequencies would be a behavioral artifact and not evidence for a low level of trophic interactions. However, the low-frequency pattern is consistent with other more compelling lines of evidence discussed in the text. 26 (27) . In contrast, the overall shift observed here for the entire Phanerozoic history of drilling in brachiopods is È3% and represents a slow increase over a period of È500 million years. 30. C. W. Thayer, Science 228, 1527 (1985) . 31 . G. C. Cadée, Lethaia 17, 289 (1984 Jung Jin Koo, 5 Hyun Soo Yoon, 6 Jung Hye Hwang, 6 Youn Young Hwang, 6 Ye Soo Park, 6 Sun Kyung Oh, 4 Hee Sun Kim, 4 Jong Hyuk Park, 7 Shin Yong Moon, 4 Gerald Schatten
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Patient-specific, immune-matched human embryonic stem cells (hESCs) are anticipated to be of great biomedical importance for studies of disease and development and to advance clinical deliberations regarding stem cell transplantation. Eleven hESC lines were established by somatic cell nuclear transfer (SCNT) of skin cells from patients with disease or injury into donated oocytes. These lines, nuclear transfer (NT)-hESCs, grown on human feeders from the same NT donor or from genetically unrelated individuals, were established at high rates, regardless of NT donor sex or age. NT-hESCs were pluripotent, chromosomally normal, and matched the NT patient's DNA. The major histocompatibility complex identity of each NT-hESC when compared to the patient's own showed immunological compatibility, which is important for eventual transplantation. With the generation of these NT-hESCs, evaluations of genetic and epigenetic stability can be made. Additional work remains to be done regarding the development of reliable directed differentiation and the elimination of remaining animal components. Before clinical use of these cells can occur, preclinical evidence is required to prove that transplantation of differentiated NT-hESCs can be safe, effective, and tolerated.
Many human injuries and diseases result from defects in a single cell type. If defective cells could be replaced with appropriate stem cells, progenitor cells, or cells differentiated in vitro, and if immune rejection of transplanted cells could be avoided, it might be possible to treat disease and injury at the cellular level in the clinic (1) . By generating hESCs from human NT blastocysts, in which the somatic cell nucleus comes from the individual patient-a situation where the nuclear Ethough not mitochondrial DNA (mtDNA)^genome is identical to that of the NT donor-the possibility of immune rejection might be eliminated if these cells were to be used for human treatment (2, 3).
Recently, mouse models of severe combined immunodeficiency (SCID) (4) and Parkinson_s disease (PD) (5) have been successfully treated through the transplantation of autologous differentiated mouse embryonic stem cells (mESCs) derived from NT blastocysts, a process also referred to as therapeutic cloning (6) . In 2004, evidence was presented that a human NT-hESC line (NT-hESC-1) was derived by transferring the donor_s cumulus cell nucleus into her own enucleated oocyte (6); however, questions remained as to whether the cell line had a parthenogenetic origin. In addition, it was not known whether NT-hESCs could be generated from NT procedures using nuclei from males, prepubescent girls, or postmenopausal women, or when using cell components from unrelated women. Finally, because NT-hESC-1 was grown on mouse feeders with likely xenograft contamination (7), the utility of those cells is largely preclinical. In our study, patientspecific NT-hESCs were established reliably and efficiently (È1 NT-hESC line per oocyte donation cycle) on human feeder cells and regardless of somatic cell donor sex or age. In addition, some lines were derived without the animal products used during immunosurgery. Immunosurgery exposes the ESC precursors, the inner cell mass cells (ICMs), through lysis of the blastocyst_s outer trophectoderm cells by sequential exposure to antibodies followed by complement; however, residual animal byproducts, including calf serum and enzymes, still remain. Furthermore, 10 of the 11 new cell lines were generated from NT procedures using oocyte and somatic cell donors that were obtained from biologically unrelated individuals.
Oocyte donations by healthy women (with cell line -8 as the only exception) and somatic cell donations by patients conformed to the regulations and law in the Republic of Korea, in accordance with responsible institutional review board (IRB) review and oversight (8) . Donors were fully aware of the scope of this study and each signed an informed consent form. Both of the parents of children under 18 years old donating somatic cells were similarly counseled, and each signed informed consent forms on behalf of their child. Patients voluntarily donated oocytes and somatic cells for therapeutic cloning research and relevant applications but not for reproductive cloning. Although expenses for public transportation and injections administered by medical personnel could have been provided, none of the donors requested this, and therefore no financial reimbursement in any form was paid (9) .
Recruited patients had a genetic immunodeficiency disease Econgenital hypogammaglobulinemia (CGH)^, disorders caused by injury Espinal cord injury (SCI)^, or another condition caused by complex autoimmune mechanisms Ejuvenile diabetes (JD)^. These three diseases are proposed to be treatable by single-cell-type transplantation with hematopoietic stem cells (of mesodermal origin), motor neurons or neuroprogenitors (ectodermal origin), or b-islet cells (endodermal origin), respectively. Patient-specific stem cells derived in this study are now expected to provide cells in a disease state that can be used to understand disease progression and assist in drug development. Because the stem cells generated with the use of patient cells are still likely to be defective, they probably cannot be directly used in cell transplantation to patients. In addition, before the cells can be used in the clinic, the biological properties of the patient-specific NT-hESCs must be defined, reliable differentiation procedures must be established, and the cells must be free of contaminating undifferentiated cells and potential pathogens.
Donor patients_ fibroblasts were grown from skin biopsies (9) . Individual cells were retrieved from the monolayer by trypsinization (9) . Heterologous NTs were performed, in which donor somatic cell nuclei were transferred individually into enucleated oocytes from a biologically unrelated individual. However, for one cell line, NT-hESC-8, autologous NT was performed, in which the donor_s own fibroblast nuclei were transferred into her own enucleated oocytes. Nine of the generated lines (and one of the unsuccessful attempts) used donated oocytes from unrelated individuals (biological or otherwise), whereas another successful line and one unsuccessful attempt used oocytes from a biologically unrelated family member. Details on oocyte and somatic cell donations and ovarian stimulation protocols are described, and the Korean version and translations by the Korean team into English of the informed consent forms are appended in (9) . Enucleation, confirmation of the oocyte_s DNA removal, NT, fusion, and activation were performed as described (6) .
Eleven NT-hESC lines were derived using somatic cells from patients with SCI, JD, and CHG of both sexes and ranging from 2 to 56 years old (Table 1 ). Figure 1 shows results from male NT-hESC-2 (left columns) and female NT-hESC-3 (right columns), in which stem cell colonies display characteristic cobblestone-like appearances with circumscribed borders (Fig. 1, A *Autologous SCNT was performed; that is, the donor's own fibroblast nuclei were transferred back into her own enucleated oocytes.
.Successful NT development without blastocyst formation.
-Rates with oocytes donated by women G30 years old (table S3) . Fig. 1N ) karyotypes are shown for NT-hESC-2 and NT-hESC-3, respectively. For complete data on NThESC-4 through -11, see fig. S1 , B and C, and Table 2 . DNA fingerprinting with human short tandem-repeat probes (Fig. 2 and fig. S2 , A to D) shows with high certainty that every NT-hESC line derived here originated from the respective patient donor and that these lines were not the result of enucleation failures and subsequent parthenogenetic activation. In Fig. 2 (red) , isogenic analysis in the loci amelogenin, D5S818, and the fibrinogen alpha chain gene (FGA) shows that the male lines -2 and -4 each precisely match the respective DNA fingerprints of the male NT donors, just as the female line -3 is an identical match with NT-hESCs have been efficiently established from a diverse group of patients. In Table 1 , the somatic cell donor_s sex, age, and disorder or disease (Table 1B) are shown in the left columns for each of the 11 new NT-hESC lines (NT-hESC-2 to -12; Table 1A ). Eighteen women donated 185 oocytes for these studies (Table 1C) , of which 125 oocytes were donated by 10 women under 30 years old (Table 1C , bottom row). On average, 10.2 oocytes were donated during each assisted reproductive technology (ART) stimulation cycle, and an average of 12.5 oocytes were donated per cycle by women under 30 (Table 1C , bottom row). Success varied, with nine lines derived from single cycles (Table 1C) . NT-hESC-2 was established with five oocytes from a single cycle, but the derivation of NT-hESC-12 required 48 oocytes from five cycles (however, four of these donations were by women over 30; Table 1C ). Lines NT-hESC-4 and -5 were established from a single cycle, as were NThESC-6 and -7 (Table 1C ). The only line in which the oocytes and somatic cell were biologically related was NT-hESC-8, in which (Table 1C) . Only two NT-hESC attempts ENT-hESC attempt I, with oocytes from two donors (one donation from a woman older than 30), and attempt II, with a single donor_s oocytes^were unsuccessful; i.e., NT constructs did not develop into blastocysts (Table 1A , bottom rows). Blastocyst development after NT occurred at high rates, with 129 fused NT constructs recovered from the original 185 injected oocytes (69.7%; range from 33.3 to 95.5%; Table 1D ). Thirty-one NT blastocysts (24.0% of the fused NT oocytes; Table 1E ) were generated. This rate was less than half the È60% in vitro fertilization (IVF) blastocyst development rate with gametes from infertility patients reported by ART clinics (10) .
Eleven NT-hESC lines were established from these 31 NT blastocysts (Table 1F; NT-hESCs per oocyte), and the other nine lines were derived from the 125 oocytes donated by younger women (7.2%). It is premature to conclude whether technical confounders, the natural variability of oocytes and donor nuclei, or individual patient characteristics account for either very favorable outcomes (when some lines were established with a few oocytes) or unsuccessful outcomes Ewhen NT-hESCs were not generated (Table 1 , attempts I and II)^.
Stem cells are defined (13) by their ability to self-renew as well as differentiate into somatic cells from all three embryonic germ layers: ectoderm, mesoderm, and endoderm. Differentiation of 7 of the 11 new NT-hESC lines (NT-hESC-2 through -11) ( Table 2) was fig. S2A ). Isogenic analysis in loci amelogenin (chromosome location: X, p22.1 to 22.3; Y, p11.2); D5S818 (chromosome location 5p22 to 31); and FGA (chromosome location 4q28) is shown. The boxed numbers and corresponding peaks represent locations of polymorphisms for each short tandem-repeat marker at loci amelogenin (peak: X, Y); D5S818 (peak no. 9 to 13); and FGA (peak no. 18 to 26). Figure S2 provides additional DNA fingerprinting evidence.
analyzed both in teratomas (Fig. 3, A to X) and into embryoid bodies (EBs) (Fig. 3, Y to e, and  fig. S3 ), and the remaining four cell lines investigated so far differentiated only in embryoid bodies (Table 2) . Each NT-hESC line differentiated into all germ layers. The convoluted surfaces characteristic of ectodermal lineages, including skin epithelium, and retinal and primitive neuroepithelium, are shown in Fig.  3, A, B, I , J, Q, and R. Muscle cell bundles, distinctive cartilage nodules, renal tubules, and bone matrix, all derived from mesoderm, are shown in Fig. 3, C, D, G, K, L, O , Q, S, T, W, and X. Endoderm derivatives, including gastrointestinal and respiratory epithelia, are shown in Fig. 3 , E to H, M, N, P, U, V, and X. Figure S3 shows panels of immunohistochemical markers specific for each lineage in every line analyzed to date ( Table 2 ).
The discoveries of Wilmut et al. (14) in sheep cloning, together with those of Thomson et al. (1) in deriving hESCs, have generated considerable enthusiasm for regenerative cell transplantation based on the establishment of patient-specific hESCs derived from NT blastocysts generated from a patient_s own nuclei. This strategy, aimed at avoiding immune rejection through autologous transplantation, is perhaps the strongest clinical rationale for therapeutic cloning. By the same token, derivations of complex disease-specific NT-hESCs may accelerate discoveries of disease mechanisms. For cell transplantations, innovative treatments of murine SCID and PD models with the individual mouse_s own NT-mESCs are encouraging (4, 5) . Human populations, unlike those of inbred mice, are genetically very diverse; consequently, conclusive proof of immune matching between the specific patient and her or his individualized NT-hESC line demands rigorous evidence. Toward this immune matching, MHC human leukocyte antigen (MHC HLA) isotypes of our stem cell lines are identical to those of the somatic cells from the corresponding patient donors (Table 3 for lines NT-hESC-2 through -4; table S4 for lines -5 through -12). MHC-HLA matching is crucial for immunological tolerance during organ donations, and in the absence of MHC-HLA matching, immunosuppressive medicines are required. This MHC-HLA matching provides additional evidence that parthenogenetic errors had not occurred. Each NThESC line matches the respective donor_s for all HLA isotypes shown in Table 3 and table  S4 , suggesting that transplanted NT-hESCs will be tolerated. Yet caution is warranted in extrapolating from these in vitro data. Some histocompatibility antigens traffic through mitochondria (15) , and mitochondria in these NT-hESCs are likely to be of either oocyte or heteroplasmic origin (except for autologous NT-hESC-8 and the original NThESC-1); thus, meticulous preclinical tolerance investigations in relevant preclinical animal models are a prerequisite for any consideration of clinical experimentation.
NT-hESCs were derived from 35.4% of the NT blastocysts (11 NT-hESC lines/31 NT blastocysts). This rate is more than 10 times the 3.3% reported earlier (6) . In contrast, the rate of blastocyst development remains at È24%. Direct derivations from either zona-free or zonaenclosed intact blastocysts were superior to derivations by immunosurgery (Table 2) . Also, immunosurgery involves antibodies and complement, so the elimination of this method avoids animal contaminants, although alternatives for the animal enzymes and serum used in the fibroblast dissociation must now be perfected.
This 10-fold increase in NT-hESC derivation resulted from five protocol improvements discussed here, combined with 10 that were previously reported (6) . The five improvements that we developed are as follows: (i) Human feeder cells, rather than murine ones, were established from the skin biopsy of donor 2, obtained under local anesthesia, and grown in 10% fetal bovine serum, 1% nonessential amino acids, and 10 mg of penicillinstreptomycin per milliliter of culture medium at 37-C in a humidified atmosphere of 5% CO 2 and 95% air. (ii) Donor nuclei were retrieved with 0.25% trypsin-EDTA for 30 s at 37-C and monitored carefully to avoid damage. (iii) Cumulus cell removal from the recipient oocytes demanded limited hyaluronidase exposure. (iv) Direct ES derivations from NT Table 2 . Summary of patient-specific NT-hESC lines. ZF-blast, zona-free blastocyst; ImmS, immunosurgery; Plurip, pluripotent. The check marks denote pluripotency demonstrated by both EBs and teratomas. Normal karyotypes have been shown for each line. Lines derived from male patients are shown in blue; lines derived from female patients are in pink. blastocysts were performed, rather than immunosurgery (Table 2) . (v) Scientist-specific micromanipulation improvements were made during the most exacting steps of the oocyte_s enucleation and during NT injection and fusion. The previous 10 important steps for NT blastocyst development are presented in (6, 9) . Neither autologous cytoplasmic matches nor fructose now appears essential. These combined 15 steps result in an NT-hESC line established with 16.8 injected or 11.7 NT-fused oocytes Efewer if donated by women younger than 30 (13.8 injected or 10.0 fused oocytes) (  Table 1F) , which compares favorably with 10.5 oocytes donated each cycle (12.5 oocytes per cycle from women under 30 (Table 1C) . Our NT-hESC derivation rate is in line with some of the highest rates from IVF blastocysts (12) . However, direct comparisons need to be tempered by the recognition that most IVF-hESC lines have been derived from clinically discarded, frozen embryos from infertility patients (11, 12) , whereas our studies relied on only prime fresh oocytes donated by fertile women expressly for this research.
Here we have described the establishment of patient-specific NT-hESCs with high success rates (Table 2) : Average rates indicating that each oocyte donation cycle leads to the establishment of one patient-specific NT-hESC line. Furthermore, discoveries of the mechanisms of complex and multifactorial diseases, also called Research Cloning, are enabled because NT-hESC-9 is derived from a patient with CGH, and NT-hESC-3 is derived from a patient with JD. By extending NT-hESC procedures from previously autologous (6) to now heterologous NT, regardless of donor patient age (2 to 56 years old) or sex, these NT-hESCs can be evaluated in vitro and after transplantation into appropriate animal models for tolerance, efficacy, and safety.
NT-hESC derivation rates from NTblastocysts increased more than 10-fold over our previous results (6) . Although the cell lines in this study were derived on human feeder cells and were found to be free of known contaminants, the method for dissociating the patient_s skin biopsy and primary fibroblast culture included fetal calf serum, trypsin, and collagenase (animal products). If preclinical results are encouraging, long before hESC lines could be used in the clinic, greater stringency is mandated, including methods to avoid xenoexposures. Furthermore, exacting documentation of the meticulous derivation, maintenance, and differentiation procedures would all need to be performed within current good manufacturer practice facilities, so that regulatory authorities such as the Korean and/or U.S. Food and Drug Administration could evaluate investigational new drug applications. However, these rates of NThESC establishment, combined with a time frame of less than 1 year from skin biopsy and oocyte donation to NT-hESC establishment, might be clinically relevant if therapeutic cloning were shown to be of medical value.
Molecular deviations between animals developing after fertilization versus those developing after reproductive cloning have been noted. In particular, epigenetic aberrations have been discovered in the genomic imprints of both cloned fetuses and offspring, as well as their placentas (2) . Notwithstanding therapeutic interest, learning whether the erasure, reestablishment, and stability of genomic imprints in these NT-hESCs compare with those of IVF-derived hESCs (16) is essential. Other extranuclear or epigenetic influences include mitochondrial inheritance patterns in hESCs, let alone those in NThESCs, which are not understood. mtDNA heteroplasmy (17) could influence hESC stability or differentiation, as might homoplasmic oocyte mtDNA incompatibilities with the donor nucleus. Furthermore, the cells_ mitotic spindle poles, or centrosomes, which are contributed by the sperm during human fertilization (18) and which, if imbalanced, have been shown to cause cancers (19, 20) , might replicate or divide inaccurately, leading to aneuploidies. Consequently, learning whether somatic centrosome transfer occurs during human NT, as it does during bovine NT (21) , is important. Inactivation of the X Figure S3 shows differentiation details for all NThESC lines. Magnification: Â100, (A) to (R); Â200, (S) to (Y). Scale bars, 100 mm. chromosome, which is typically random in female mammals, is skewed in cloned female mice (22, 23) , causes recurrent spontaneous abortions in some pregnant women (24) , and could result in misexpressions in NT-hESCs derived from women. Finally, the genomic stability of NT-hESCs, as well as their differentiation fidelity, including aging and telomerase/telomere behavior, also require rigorous investigations.
The somatic cell_s adaptation to in vitro conditions may predispose human NT embryos to cell culture proliferation, with negligible potentials for implantation and none for normal development. Neither NT embryonic development nor NT-hESC establishment rates provide any encouragement for dangerous human reproductive cloning attempts. Cloned animals have adverse pregnancy outcomes, so regardless of cruel hoaxes (25) , scientific evidence should further discourage reckless notions regarding human reproductive cloning. Human SCNT was optimized from porcine SCNT procedures in which È150 NT embryos were transferred for pregnancy establishment (26) (27) (28) . Furthermore, in rhesus monkeys, 135 cloned embryos transferred into 25 surrogates using some of these improved SCNT techniques (29) did not result in any pregnancies, although rhesus NT blastocysts developed and NTICMs were isolated.
Our work described here shows that stem cell lines can be generated using somatic cells from patients with disease and injury. It may also be possible to generate NT-hESC lines from patients with diseases and disorders of unknown causes. For example, NThESCs derived from early-onset Alzheimer_s disease or autism patients might prove invaluable for mechanistic studies in vitro after differentiation into neuroprogenitors (30, 31) . In addition, biological insight gained through studying hESCs might find application to ART and assist in understanding genomic imprinting. The derivations of patient-specific NThESCs grown without animal cell co-culture may advance cell transplantation therapies as well as aid in the discovery of human developmental processes and the causes of many complex diseases. Table 2 . The corrected table appears here. 
